Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.

NCT Number	NCT05595499
Lead Sponsor	Jonsson Comprehensive Cancer Center Collaborators: National Cancer Institute (NCI), National Institute on Aging (NIA)
Conditions	Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Enrollment	88 participants
Start Date	2023-03-27
Primary Completion	2027-08-14 (estimated)
Study Completion	2028-08-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-17